Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition (Q38195808)

30 August 2017

1 reference

title

Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition (English)

1 reference

30 August 2017

Minjie Lin

1

1 reference

30 August 2017

Shuiping Zhao

series ordinal

2

1 reference

30 August 2017

Li Shen

series ordinal

3

1 reference

30 August 2017

Danyan Xu

series ordinal

4

1 reference

30 August 2017

publication date

1 April 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

37

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

213-224

1 reference

Microsomal triglyceride transfer protein

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Targeting PCSK9 for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

The role of the microsomal triglygeride transfer protein in abetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Multiple functions of microsomal triglyceride transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Microsomal triglyceride transfer protein enhances cellular cholesteryl esterification by relieving product inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Mammalian acyl-CoA:cholesterol acyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Microsomal triglyceride transfer protein inhibition induces endoplasmic reticulum stress and increases gene transcription via Ire1α/cJun to enhance plasma ALT/AST

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Review of treatment options for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Review article: Non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Piperine, the potential functional food for mood and cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Piperine, an LXRα antagonist, protects against hepatic steatosis and improves insulin signaling in mice fed a high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Piperine reverses high fat diet-induced hepatic steatosis and insulin resistance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Experimental studies of oxymatrine and its mechanisms of action in hepatitis B and C viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Hepatoprotective effects of Juglans regia extract against CCl4-induced oxidative damage in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Dietary walnut oil modulates liver steatosis in the obese Zucker rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Walnut oil increases cholesterol efflux through inhibition of stearoyl CoA desaturase 1 in THP-1 macrophage-derived foam cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Acute consumption of walnuts and walnut components differentially affect postprandial lipemia, endothelial function, oxidative stress, and cholesterol efflux in humans with mild hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Statins as anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Long‐Term Statin Therapy Affects the Severity of Chronic Gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

The lipid and non-lipid effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Liver X receptors as integrators of metabolic and inflammatory signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Liver X receptor and farnesoid X receptor as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Mouse models for atherosclerosis and pharmaceutical modifiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Acyl-CoA:diacylglycerol acyltransferase: molecular biology, biochemistry and biotechnology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Inhibitory activity of diacylglycerol acyltransferase (DGAT) and microsomal triglyceride transfer protein (MTP) by the flavonoid, taxifolin, in HepG2 cells: potential role in the regulation of apolipoprotein B secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Roles of PPARs in NAFLD: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Peroxisome proliferator-activated receptor alpha plays a vital role in inducing a detoxification system against plant compounds with crosstalk with other xenobiotic nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Tracking immune cells during organ rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Review article: role of oxidative stress in the progression of non-alcoholic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Nonalcoholic fatty liver disease: current issues and novel treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Vitamin E and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effect of alpha-tocopherol on carbon tetrachloride intoxication in the rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Vitamin E treatment in pediatric obesity-related liver disease: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Ω-3 fatty acids prevent hepatic steatosis, independent of PPAR-α activity, in a murine model of parenteral nutrition-associated liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Where are we with probucol: a new life for an old drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Pharmacological Characterization of Diethyl-2-({3-dimethylcarbamoyl-4-[(4′-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Overview of metformin: special focus on metformin extended release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Histopathology of pediatric nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Journeys of the Circle: a culturally congruent life skills intervention for adolescent Indian drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

The role of metformin in the management of NAFLD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Pioglitazone: side effect and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Nonalcoholic fatty liver disease and lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Improvement of Insulin Sensitivity after Peroxisome Proliferator-Activated Receptor-α Agonist Treatment Is Accompanied by Paradoxical Increase of Circulating Resistin Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Subcutaneous vitamin E ameliorates liver injury in anin vivo model of steatocholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0147-X

Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate

21 January 2018

1 reference

12 December 2020

Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America

1 reference

12 December 2020

A position statement on NAFLD/NASH based on the EASL 2009 special conference

1 reference

12 December 2020

Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats

1 reference

12 December 2020

Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis

1 reference

12 December 2020

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis.

1 reference

12 December 2020

Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver

1 reference

12 December 2020

Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats

1 reference

12 December 2020

Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results

1 reference

12 December 2020

Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study

1 reference

12 December 2020

Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARalpha

1 reference

12 December 2020

Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis.

1 reference

12 December 2020

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

12 December 2020

Antioxidant therapy in nonalcoholic steatohepatitis

1 reference

12 December 2020

Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease

1 reference

12 December 2020

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

12 December 2020

Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?

1 reference

12 December 2020

Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet

1 reference

12 December 2020

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

1 reference

12 December 2020

Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man

1 reference

12 December 2020

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

1 reference

12 December 2020

Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.

1 reference

12 December 2020

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

1 reference

12 December 2020

Saying "Yes" to obese living liver donors: short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation

1 reference

12 December 2020

Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation

1 reference

12 December 2020

Weight reduction for non-alcoholic fatty liver disease

1 reference

12 December 2020

Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study

1 reference

12 December 2020

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

12 December 2020

The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis

1 reference

12 December 2020

Therapy of NAFLD: antioxidants and cytoprotective agents

1 reference

12 December 2020

10.1007/S40264-014-0147-X

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1051400120

0 references

1 reference